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Abstract
In the light of recent National Institute for Clinical Excellence (NICE) and
Committee for the Safety of Medicines (CSM) guidance we discuss the
importance of the diagnosis of depression in old age and review
pharmacological interventions. An introductory section is followed by
sections on each of the main antidepressant groups. This briefly describes
their pharmacology and reviews research done specifically relevant to older
people. Finally practical clinical applications are discussed.
Introduction
NICE guidance on management of depression is quite specific and detailed
(see Box 1). According to NICE “watchful waiting” and “guided self help”
are the best strategies for mild depression. For moderate or severe
depression medication, psychological interventions and social support are
appropriate. They can, in the first instance, be delivered in primary care.
Where depression is treatment resistant, atypical, recurrent or psychotic or
where there is “significant risk” specialist mental health teams should be
involved using medication, complex psychological interventions and/or
combined treatments. (In the experience of the authors this includes many
older people with moderate and all with severe depression.) Finally, where
there is risk to life or severe self-neglect crisis intervention and inpatient
care with medication, combined treatments and ECT may be needed.
Box 1 Key points from NICE guidance on the management of
depression (modified)
• Screening is justified in high risk sub groups, for example those with
chronic disability or in hospital or residential care
• Guided self help (where the patient wants it) or “watchful waiting”
with a further assessment within two weeks is the correct
intervention for mild depression. Antidepressants are not
recommended for this group.
• Short term psychological treatment specifically focused on
depression is recommended for mild to moderate depression
• SSRI antidepressants are the first choice drugs for uncomplicated
moderate depression but other drugs also make a major
contribution particularly in more severe or resistant depression
• Patients should be fully informed about medication including
discontinuation symptoms
• In severe depression the combination of cognitive behavioural
therapy (CBT) with medication should be considered as it is more
effective than either treatment alone.
• In recurrent depression continuation of antidepressants for at least
two years and CBT both have a role
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It is essential that high quality psychological interventions are made
available to older people (Everybody’s Business, 2005). There is a need for
research into the availability of these interventions but a description of them
is beyond the scope of this review. A comprehensive account of Cognitive
Behavioural Therapy (CBT) with Older Adults can be found in Laidlaw et al
(2003).
Depression in later life is very similar to depression at other times of life and
some have argued that there is insufficient evidence for a subtype of major
depression in older people (Baldwin et al., 2002) though this is not a
universally held view. However, ageing and other factors may alter the
presentation of depression in later life. In particular older people are less
likely to complain of sadness compared with younger patients and they are
more likely to complain of physical symptoms, memory complaints and
anxiety symptoms (Baldwin et al., 2002). In addition, depression in patients
with dementia may lead to behavioural disturbance (Dwyer and Byrne,
2000).
Depression also has a significant impact on individual patients, their
families and society more generally. In particular, depression is one of the
leading causes of disability, it leads to a greater risk of hospitalisation as
well as inappropriate bed use and prolonged hospitalisation; it is the single
most important predictor of suicide. It also reduces compliance with medical
treatments, reduces the patient’s quality of life and is an independent
predictor of mortality (Baldwin et al., 2002).
Prevalence
Depression is two to three times more prevalent than dementia and is the
most common mental health problem amongst older adults. In community
samples the prevalence of mild depression has been estimated to be 11%
(Alexopoulous, 1992), rising to 22- 33% in residential and nursing homes
(Ames et al., 1988) and 45% in hospitalised older patients with physical
illness (Koenig et al 1988). Depressive disorder, disability and dependency
are all highly correlated and it is important to consider the diagnosis of
depression in these settings.
Aetiology
A number of risk factors for depression have been identified. Genetic
susceptibility is less important in depression when onset is in later life.
Females are more susceptible to depression. A previous history of
depression is an important predisposing factor and widows, widowers and
divorcees are more susceptible to depression. Neurotransmitter changes
are also well recognised in older people including reductions in
noradrenalin and serotonin (Hindmarch, 2001). There are a number of
other brain changes including cerebral atrophy but it is not entirely clear if
this is related to depression. Deep white matter lesions and sub cortical
grey matter lesions seem to be commoner in late onset depression (Curran
and Wattis, 2004). Epidemiological studies have highlighted an association
between hypertension and depression as well as other vascular risk factors
including smoking, excessive alcohol consumption and hypotension.
Personality factors are important predisposing factors particularly avoidant
and dependent personality types. There is a strong association between
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disability (functional limitation) due to medical conditions and depression
and especially with pain (Stahl and Briley, 2004). Being a carer of someone
who is chronically ill is another important risk factor. Precipitating factors
include life events such as bereavement, separation, acute physical illness,
moving into residential care and chronic stress. A number of drugs can also
cause or aggravate depression including beta-blockers, methyldopa,
reserpine, clonidine, calcium channel blockers, digoxin, codeine, opioids,
indomethacin, steroids, L-Dopa, amantadine, tetrabenazine, antipsychotics
and benzodiazepines. Some factors can be protective including good
medical care including general health, nutrition and physical fitness, good
coping behaviours e.g. adaptive personality, capacity for confiding
relationships and good social support including religious/spiritual beliefs
(Baldwin et al., 2002).
Association with physical illness
Depression is an independent risk factor for a number of medical conditions
including stroke (Jonas and Mussolino, 2000) and heart failure (Ariyo et al.,
2000). Depressive symptoms also add to the disability from physical illness
and are associated with physical decline (Penninx et al., 2000). A number
of medical conditions increase the risk of depression including
hypo/hyperthyroidism, Cushing’s disease, hypercalcaemia, pernicious
anaemia, cerebrovascular disease, Parkinson’s disease, Alzheimer’s
disease, SLE, cancer, particularly of the lung and pancreas, and chronic
infections such as brucellosis.
Classes of antidepressants
Tricyclic antidepressants (TCAs)
All these compounds are inhibitors of noradrenalin uptake with a variable
potency of inhibiting serotonin uptake as well. They include amitriptyline,
imipramine, dothiepin, doxepin, nortriptyline and lofepramine. Tricyclics can
be subdivided into secondary (e.g. nortriptyline) and tertiary amines (e.g.
imipramine and amitriptyline). Secondary amines are predominantly
noradrenaline re-uptake inhibitors.
These drugs are generally well absorbed orally. They are lipophilic and
widely distributed in the body. They are metabolised in the liver and some
of the metabolites are active antidepressants. The major route of
elimination is renal excretion. The lower rates of both hepatic metabolism
and decreased renal clearance in this age group may reduce the dosage
needed to achieve a given blood level. Some clinicians have recommended
plasma level monitoring for TCAs in older patients but this is seldom done
in clinical practice. Lofepramine has minimal anticholinergic properties and
cardiac toxicity in older patients by comparison with older TCAs.
Drugs with a tertiary amine structure tend to produce more antagonism of
α1 adrenergic receptors with subsequent hypotension, blockage of
histamine (causing sedation) and cholinergic receptors (causing dry
mouth, blurred vision, urinary retention, dizziness, tachycardia, memory
impairment and at high and toxic doses, delirium). The tendency to produce
orthostatic hypotension is a serious side-effect in the older patients leading
to an increased risk of falls and limb fracture.
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Clinical studies
There are a limited number of double-blind, placebo-controlled trials of
antidepressants involving older people and most of these are of TCAs
(Mittman et al., 1997; Wilson et al., 2001). There is some evidence that
TCAs are more effective than SSRIs in treating severe depression in older
people (Navarro et al., 2001).
Patients commenced on TCAs often receive sub-therapeutic doses for
inadequate periods of time compared with SSRIs (Donoghue and Hylan,
2001). However, a recent Cochrane review found that treatment of
depression with low dose tricyclics is justified (Furukawa et al., 2004). In
addition, a further Cochrane review of amitryptyline for older people found
that it was at least as effective as other TCAs (in therapeutic doses) and
newer compounds, especially SSRIs, but patients taking amitriptyline
experienced a higher prevalence of side-effects (Guaiana et al., 2004).
Selective serotonin reuptake inhibitors (SSRIs)
SSRIs have a selective effect on serotonin reuptake, making them less
likely to cause the side-effects encountered with TCAs. They include
fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram and escitalopram.
These drugs are rapidly absorbed from the gut and broken down into
several metabolites (often with antidepressant activity) each with different
half-lives. All SSRIs are extensively protein-bound. The plasma half-lives
of fluvoxamine and fluoxetine are relatively unaffected by age whilst steady-
state plasma concentration of paroxetine, sertraline and citalopram are
higher in the elderly and elimination half-life is longer than for the same
dose in adult patients (Baumann, 1998). Paroxetine has also some affinity
for muscarinic receptors making it the most sedative SSRI. Administration
of all SSRIs can augment TCA activity, as well as other drugs metabolised
by the hepatic cytochrome P450 system. These interactions tend to be
dose dependent.
All SSRIs are effective (65% response rate) and well tolerated in older
depressed patients (Baumann, 1998). They are relatively free of
anticholinergic effects and cardio toxicity, and cause less postural
hypotension than TCAs. Their main side-effects include headache, nausea,
diarrhoea, insomnia, dizziness, and sexual dysfunction. All the SSRIs, with
the exception of citalopram and sertraline, cause clinically relevant drug-
drug interactions through their inhibitory effects on the cytochrome P450
system. Paroxetine, fluoxetine and fluvoxamine have inhibitory effects on
cytochrome P450 isoenzymes that can lead to increased plasma levels of
antipsychotics and TCAs (Anderson and Edwards, 2001). The half-lives of
sertraline, citalopram, and paroxetine are prolonged in the older patients
(Baumann, 1998) and lower starting doses of paroxetine (10mg/day) and
perhaps citalopram may be needed. Elimination of citalopram, fluoxetine,
sertraline and fluvoxamine are decreased in hepatic impairment and
paroxetine elimination is reduced in renal impairment.
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Clinical studies
Wilson et al (2001) found that in older people with depression the number
needed to treat for a therapeutic response to a TCA was 4 whereas for
SSRIs the number was 7. However, only two trials met criteria for the
analysis and both of these involved fluoxetine.
Sertraline is well tolerated in patients with major depression and acute MI
or unstable angina. This study involved 369 patients many of whom were
over 65 with a mean age of 57.1 years (Glassman et al. (2002). Sertraline
was also effective and well tolerated in patients with co morbid medical
illness in a randomised controlled trial (RCT) (with placebo) involving 752
older patients (Sheikh et al., 2004).
In a more recent long-term study looking at depression in older people, 254
patients were treated with sertraline and entered the treatment (8 weeks)
and continuation phases (16-20 weeks) of the study. 113 patients entered
the maintenance phase (100 weeks) and randomised into a double-blind,
placebo controlled continuation/maintenance phase of approximately 2
years duration. No significant difference between the sertraline and placebo
groups was found in the proportion of recurrences. The authors concluded
that sertraline at therapeutic dosage does not provide significant protection
against recurrence. However, very small numbers finished the trial (Wilson
et al., 2003).
In a recent RCT involving 319 older patients with major depression,
paroxetine controlled-release (CR) was compared with paroxetine
immediate-release (IR) and placebo over 12 weeks. Both active treatments
were more effective than placebo and responders were 72% (CR), 65%
(IR) and 52% for patients on placebo and these were significantly different
(Rapaport et al., 2003).
Citalopram is well tolerated in older patients and in a review of 1344
patients from RCTs treated for a minimum of 6 weeks, bradycardia was
significantly more likely in older people (2.4% versus 0.2%) whereas
gastrointestinal side-effects, sweating and headache were less prevalent in
older patients (Barak et al., 2003). There have been no published reports of
escitalopram in older people (Bielski et al., 2003).
The Committee on Safety of Medicines in 2004 issued general guidance on
the use of SSRIs. The report examined SSRIs in both children and adults
and focused particularly on suicidal behaviour and withdrawal reactions. In
relation to adults the report concluded that “From the available clinical trial
data, both published and unpublished, a modest increase in the risk of
suicidal thoughts and self-harm for SSRIs compared with placebo cannot
be ruled out. There is insufficient evidence from clinical trial data to
conclude that there is any marked difference between members of the
class of SSRIs or between SSRIs and other antidepressants with respect to
their influence on suicidal behaviour”. In relation to withdrawal reactions the
report concluded that “All SSRIs may be associated with withdrawal
reactions on stopping or reducing treatment. Paroxetine and venlafaxine
seem to be associated with a greater frequency of withdrawal reactions
than other SSRI” (CSM, 2004)
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Serotonin and noradrenaline reuptake inhibitors (SNRIs)
Venlafaxine selectively inhibits the uptake of serotonin and noradrenaline
and in comparison with TCAs show no affinity for other neuroreceptors
(Mendlewicz, 1995). No dosage adjustments are recommended for older
people. Compared with SSRIs, venlafaxine affects the cytochrome P450
enzyme system relatively little. The most common side-effects include
nausea, headache, dry mouth, dizziness, constipation and hypertension,
although postural hypotension can be a problem in older people and should
be monitored. To minimise risk of discontinuation symptoms, the dose of
venaflaxine should be gradually tapered over a few weeks period. SSRIs
and venlafaxine are also associated with hyponatraemia in older patients
(Kirby et al., 2002).
Clinical studies
Venlafaxine is well tolerated (Danjou and Hackett, 1995) and shows similar
efficacy to TCAs (Mahapatra and Hackett, 1997). There is evidence that
the efficacy of venlafaxine is dose related and that at higher doses
(>150mg daily) venlafaxine is more effective than SSRIs in major
depression (Smith et al., 2002).
In a RCT comparing dothiepin and venlafaxine in 92 older patients with
major depression, response to therapy in the venlafaxine group was 60%
compared with 53% in the dothiepin group but these were not significantly
different. Side-effects were very similar in the two groups and not
significantly different (Mahapatra and Hackett, 1997).
In a 10-week randomised-controlled, double-blind trial of venlafaxine (up to
150 mg/day) versus sertraline (up to 100 mg/day) in 52 older nursing home
patients with major depression, venlafaxine was less well tolerated but
there were no significant differences in response to treatment (Oslin et al.,
2003).
However, in a systematic review of eight RCTs, remission rates were
significantly higher with venlafaxine compared with an SSRI in a series of
studies involving over 2000 patients but the mean age in all groups was
approximately 40 years (Thase et al., 2001). In addition, in a recent RCT
involving eight older patients, venlafaxine 37.5mg bd had no significant
effects on cognition or psychomotor performance compared with dothiepin
(Trick et al., 2004).
Recent advice has been issued by the Committee on Safety of Medicines
(2004) in relation to venlafaxine. In summary, venlafaxine should only be
initiated by specialist mental health practitioners or GPs with a special
interest in mental health and there should be appropriate supervision of
patients. Venlafaxine should not be initiated in patients with heart disease
e.g. cardiac failure, coronary artery disease, patients with ECG
abnormalities including QT prolongation, in patients with electrolyte
disturbances and in patients with hypertension. Patients currently taking
and tolerating venlafaxine and getting clinical benefit should continue to the
end of the course (CSM, 2004).
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Recently duloxetine became available. It is also a dual uptake inhibitor of
both serotonin and noradrenaline with comparable affinities for both
systems. A number of studies in younger patients have shown it to be
effective with good safety and tolerability (Hudson et al., 2005) and as well
as being effective and well tolerated in older people with depression
(Nelson et al., 2005) but further work is needed.
Monoamine oxidase inhibitors (MAOIs)
Traditional MAOIs include phenelzine, isoniazid and tranylcypromine.
These bind non-selectively, either irreversibly or almost so, to both type A
and type B monoamine oxidase enzymes to prevent the destruction of
endogenous catecholamines (noradrenaline and dopamine) and the
sympathomimetic amine tyramine. Because they lack selectivity, traditional
MAOIs can lead to serious side-effects when foods rich in tyramine or other
amines are eaten. In addition, these drugs have significant interactions with
other drugs that seriously limit their use compared with other
antidepressants. However, they may have a place in the treatment of
resistant depression (Georgotas and McCue, 1989), but they are seldom
used as first line drugs. There is no good quality data specifically in relation
to depression in older people.
Reversible inhibitor of monoamine oxidase (RIMA)
These drugs preferentially inhibit monoamine oxidase A but the inhibition is
reversible. Moclobemide is effective and well tolerated and may be a useful
alternative for depressed patients with prominent anxiety symptoms
(Tourigny-Rivard, 1997). In addition, it may enhance cognition in dementia
with depressive symptoms (Roth et al., 1996). It lacks anticholinergic and
cardio toxic side-effects but it can cause insomnia and nausea. Drug
interactions can occur with sympathomimetics and opiates but unlike
traditional MAOIs it requires little or no dietary restrictions. Bonnet (2003)
has recommended combining moclobemide with another antidepressant
e.g. clomipramine or an SSRI for treatment resistant depression. However,
these combinations are not without risks.
Noradrenaline and serotonin synaptic antagonist (NaSSA)
Mianserin and mirtazapine are both potent antagonists at α2-autoreceptors.
This leads to an increase in noradrenaline release. These drugs have low
affinity for muscarinic, cholinergic and dopamine receptors resulting in
reduced side-effects. Mianserin has fallen out of favour because of a small
risk of agranulocytosis necessitating blood monitoring and there is very little
data in older patients. Mirtazapine has effects on both the noradrenergic
and sertonergic systems. It enhances central noradrenergic and 5HT1-
receptor mediated serotonergic neurotransmission. It is also an antagonist
at α2 presynaptic autoreceptors and also blocks 5HT2 and 5HT3 receptors.
This results in increased noradrenergic release. Changes in
pharmacokinetics with age are considered minor (Timmer et al., 1996).
The main side-effects of mirtazapine include sedation and weight gain and
less commonly mania, convulsions, paraesthesia and reversible
agranulocytocis.
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Clinical studies
Mirtazapine (maximum 35mg) has been compared with trazodone
(maximum 280 mg) in a placebo-controlled, double-blind trial over 6 weeks
involving 150 older patients with major depression. Significant
improvements in depression were observed with both active compounds
from week 2 compared with placebo. However, both drugs had significantly
higher levels of somnolence and dry mouth and trazodone dizziness, and
blurred vision (Halikas, 1995).
A similar study compared mirtazapine with amitriptyline (30-90 mg) in 115
older depressed patients in a double-blind, multi-centre study. Similar
clinical benefit was observed with both drugs but the Clinical Global
Impression (CGI) was statistically better in the amitriptyline group. Side-
effects were noted to be similar in both groups (Hoyberg et al., 1996)
In a recent RCT, mirtazapine was compared with paroxetine over 8 weeks
in 255 older patients with major depression. Mirtazapine had a significantly
earlier onset of action and was better tolerated (Schatzberg et al., 2002).
Noradrenaline re-uptake inhibitors (NARIs)
Recent evidence suggests that reboxetine is effective in older people with
depression but causes less hypotension and fewer serious side-effects
than TCAs (Katona et al., 1999). However, renal clearance is reduced in
older patients (Bergmann et al., 2000). The pharmacokinetics of reboxetine
are linear following both single and multiple oral doses and the plasma half-
life is approximately 12 hours. Metabolism is mainly via the liver with only
10% cleared by the kidneys but plasma concentrations are increased in
older patients.
In a prospective, uncontrolled, multi centre study of reboxetine involving
160 older patients with major depression over 52 weeks, 104 patients
completed the study. The proportion who were rated as either “much” or
“very much improved” were 15.1% at 2 weeks and 88 % at 6 weeks with
95.2% at 52 weeks. The drug was well tolerated although nausea (11.9%)
and headache (10%) were relatively common (Aguglia, 2000). However,
because of these side-effects some authors have recommended that older
patients should be started on 4mg/day in two divided doses (Bergmann et
al., 2000). Controlled trials in older people are still needed.
Which antidepressant is best for older people?
There is no clear answer to this question. However, in a review of 18 meta-
analyses of different antidepressants mainly involving younger patients, the
main finding was a lack of major difference in efficacy between the newer
and older antidepressants. Venlafaxine was found to be superior to SSRIs
and SSRIs better tolerated. Interestingly, in older patients dothiepin was
found to be better tolerated than SSRIs (Anderson, 2001). In addition, in a
recent Cochrane review (Wilson et al., 2004) TCAs, SSRIs and MAOIs
were reported to be effective in the treatment of older community patients
and inpatients with severe physical illness. At least six weeks of
antidepressant treatment was recommended to achieve optimal therapeutic
effect.
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Antidepressants do not help everyone with depression. Although much has
been written about how to identify responders this is still difficult in clinical
practice and “trial and error” is still largely the norm.
Practical prescribing
Although depression can be successfully treated it is frequently missed and
treated with suboptimal doses of antidepressants for inadequate periods of
time. The treatment of depression in older people invariably needs an
integrated approach with pharmacological, social and psychological
approaches working together. Patient education is also an important
component of successful treatment and it is essential to work closely with
families (Wilson et al., 1999).
The optimal treatment of depression in later life is crucial and requires
appreciation of a number of factors such as co-morbidity, polypharmacy,
altered drug kinetics, variable treatment response and increased
predisposition to side effects. Older people need to be thoroughly assessed
(Curran et al., 2005) before commencing antidepressants due to the
increased incidence of physical illnesses, changes in pharmacokinetics and
increased sensitivity to side-effects. It is also an important opportunity to
develop a good rapport with patients to improve understanding of and
compliance with medication. Despite the NICE (2004) recommendation that
SSRIs are recommended and (particularly on the basis of cost-benefit,
fluoxetine or citalopram) there is no single “first line” antidepressant and
individual prescribing should take into account a number of factors
including efficacy, safety, tolerability, real-world efficacy and economic
value (Mendlewicz, 2001). Regular review is also important to monitor
compliance, response, side-effects and physical health.
Acute treatment
Approximately 70% of patients will respond to an antidepressant (Stahl,
2000) but this can be lower in older people with rates of 40-60% being
more typical (Williams et al., 2000). However, only approximately 50% of
patients with major depression achieve remission with their first
antidepressant (Pridmore and Turnier, 2004). In a recent systematic review
of 186 RCTs mainly involving younger people, amitriptyline was found to be
less well tolerated but slightly more patients recovered compared with
alternative antidepressants (Barbui and Hotopf, 2001).
Several studies have shown that the onset of therapeutic action may take
longer in older people and that optimum benefit can take 8-12 weeks after
commencing treatment (Georgotas and Cooper, 1989). When initial
treatment with a tricyclic has been ineffective a second antidepressant may
take 5-6 weeks to have an effect (Flint and Rifat, 1996). ‘Start low; go slow’
is a useful guide when prescribing in older people but with the aim of
reaching therapeutic dosages. Older patients are at high risk of recurrence
following a depressive episode, with up to a 70% risk of recurrence within
two years of remission (Flint, 1992). Therefore, after a successful response,
continuation of antidepressant medication may be needed for at least two
years.
Stephen Curran, Andrew Byrne, John Wattis
 73
Continuation treatment
How long should an antidepressant be continued for? Antidepressant drug
treatment should be continued for at least 12 months after remission in the
elderly (OADIG, 1993; Anderson et al., 2000). If antidepressant treatment is
stopped within 6-12 months and substituted with a placebo, approximately
50% of patients will relapse. In addition, if treatment is continued for 12
months, 90% will continue to respond. The risk is greater if the patient has
had a number of previous episodes e.g. 1 (<50%), 2 (50-90%) and 3
(>90%) (Stahl, 2000). Continuation drug therapy reduces the risk of relapse
after remission. It is not a fixed period but in older people a 12-month
period of continuation with antidepressants is recommended in contrast to 6
month period for younger patients (Baldwin et al., 2002). However, patients
with recurrent depression should be treated for two years (or more). For
patients with delusional depression on anti-psychotic medication, it is
recommended that this be continued for 6 months before being tailed off.
Maintenance treatment
When should maintenance therapy be used? This would usually be if there
has been two or more previous episodes for younger patients but one or
more previous episodes for older patients (Stahl, 2000).
The dose of antidepressant should be with the same dose as used to treat
the acute episode (Anderson et al., 2000). Older patients taking dothiepin
over a two- year period are 2.5 times less likely to relapse compared with
those taking placebo (OADIG, 1993). A recent study has shown that
maintenance therapy with either nortriptyline or paroxetine was effective in
80-90% of older patients over an 18-month period (Reynolds et al., 1999).
In older patients, citalopram prevented recurrence over a period of 1-2
years suggesting that protection is not confined to TCAs (Appelberg, 2002).
However, Wilson et al. (2001) did not find any benefit from sertraline in
prophylaxis. Possibly the dose used was too small. However, this study
cautions against assuming all antidepressants are equally effective in
prevention. The case for long-term antidepressant treatment needs to be
balanced against adverse effects, which in the case of older
antidepressants can include troublesome weight gain and cardiovascular
disturbance.
Lithium salts are also widely used for the prophylaxis of recurrent
depression despite lack of adequate studies in older patients. A small
prospective study by Abou-Saleh and Coppen (1983) found that an older
sub-group benefited from lithium prophylaxis. However, clearance of lithium
is reduced in older patients, so half the adult dosage may be required and
maintenance levels of 0.5mmol/l have been suggested. Lithium should be
used cautiously with SSRIs because of the risk of serotoninergic
neurotoxicity.
Management of treatment resistant depression
Treatment resistance is reported in up to 40% of older patients with major
depression (Flint, 2002). There is little evidence to guide the management
of depression that has failed to respond to a course of an antidepressant
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and further research is needed to inform clinical practice. A review of 29
studies concluded that 35-60% of older patients showed a good recovery
from a first depressive episode (Angst, 1997). However, research on
treatment resistant depression in older people is hampered in part by lack
of an agreed definition.
The definition of treatment resistant depression can be confusing. Some
have suggested that it is failure to respond to one effective medication at a
therapeutic dosage and for an adequate duration (Cowen, 1998). Renwick
(1985) has suggested that it is the failure to respond to an adequate trial of
two antidepressants or an antidepressant and/or ECT. Thase and Rush
(1997) elaborated the definition further by developing a staging system of
treatment resistance based on types of failed treatment.
The first step is to review the diagnosis and ensure that an organic cause
has not been missed. Further investigations may be necessary such as an
ECG, Chest X-ray, EEG or CT head scan. Severe deep white matter
lesions on a brain MRI scan (O’Brien and Barber, 2000) and prefrontal
dysfunction may predict a poor response to antidepressant treatment
(Kalayam and Alexopoulous, 1999). Depression in patients with
Alzheimer’s disease is more likely to resolve spontaneously without
requiring intensive antidepressant treatment compared with patients with
vascular dementia who are more likely to have persistent and treatment
resistant depressive symptoms (Li et al., 2001). The presence of a silent
cerebral infarction also reduces treatment response to antidepressant
treatment (Yamashita, 2000).
Where there are maintaining social or environmental factors, psychological
therapies may be beneficial as an adjunct to pharmacological treatment. A
recent meta-analysis of psychological outreach programmes demonstrated
a large effect size (0.7) in depressed older patients (comparable to effect
sizes found in younger adults). Cognitive behavioural therapy was found to
have a larger effect size than other therapies but also had higher drop out
rates (Cujpers, 1998).
It is also important to ensure treatment adequacy in terms of duration and
compliance. This has been called a stepped-care approach, meaning that
each step of treatment follows a logical sequence rather than a chaotic
mishmash (Guscott and Grof, 1991). This has been reinforced in a study by
Flint & Rifat (1996) in which over 80% of patients recovered if a logical
process is adopted, for example starting with a trial of antidepressant
monotherapy and eventually moving up to ECT.
Some of the specific drug-related approaches include:
Change the dose
This usually though not always means increasing the dose. This may be
beneficial for TCAs and venlafaxine but there is little evidence that
increasing the dose significantly alters the outcome in the case of SSRIs. At
higher doses (>150mg daily) venlafaxine may be more effective than SSRIs
in major depression (Einarson et al., 1999). Blood pressure monitoring is
recommended when patients are taking high doses of venlafaxine (>200mg
daily).
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Prolong the length of treatment
Here the therapeutic trial is continued beyond what is usually considered an
‘adequate’ period of time. There is evidence that an extension to nine
weeks or even longer may improve recovery from depressive episode in
older patients (Georgotas and McCue, 1989), although not if there has been
no improvement in the first four weeks (Mottram et al., 2002).
Switching antidepressant class
Switching between classes of antidepressants has been shown to have
modest benefit, although there is little systematic evaluation. The most
popular strategy is a change from one antidepressant to another from a
different class: for example from a TCA to an SSRI, or vice versa (Akiskal,
1985). Venlafaxine showed some promise in resistant depression but
evaluation is mostly confined to clinical experience (Bowskill and Bridges,
1997), or open trials (Nierenberg et al., 1994). It has been estimated that
the overall success rate for class switching is about 50% (Baldwin, 1996).
Lithium augmentation
Following failure of two classes of antidepressants, traditionally, the next
step would be lithium augmentation. As yet there have been no
randomised-controlled trials of lithium augmentation in older patients. Flint
and Rifat (1994), in an open prospective study, showed a 23% response
rate. They also found that 50% of older patients experienced side-effects
including polydipsia, polyuria, tremor, dry mouth and nausea. Fahy and
Lawlor, (2001) followed up a small cohort of older depressed patients who
had their long-term lithium augmentation therapy discontinued for varying
reasons, 52% relapsed and the longer the length of lithium treatment prior
to discontinuation the poorer the outcome. The time needed to judge
response to lithium augmentation is approximately to 2-3 weeks (Cowen,
1998).
Austin et al. (1991) conducted a meta-analysis of five small double-blind
trials and found that 18/50 of patients augmented with lithium responded
compared with 6/49 of those who were given placebo. In another study
(Hoencamp et al., 2000) venlafaxine and lithium augmentation was studied
in an open trial in out-patients aged 18-70. At the end of 7-weeks study,
35% of the patients showed a more than 50% reduction in depressive
symptoms and the combination was well tolerated. Other augmentation
approaches include use of neuroleptics, anticonvulsants, thyroid hormone
and L-tryptophan but the evidence-base is too weak to make firm
recommendations for older patients.
Combination therapies
MAOIs and TCAs combinations (+ or – lithium) has been used for decades
in resistant cases. A review by Cowen (1998) demonstrated how open
studies in younger adults have shown failure of each type of drug
individually, but with good results when combined. Starting at very low
dose, adding in the MAOI and not using imipramine or clomipramine is
thought to lessen the risks of hazardous side effects and interactions.
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There is no evidence for this combination in older people and both MAOIs
and TCAs are being used less compared with several years ago.
Other antidepressant combinations that have been tried include TCAs and
SSRIs. Again there are no controlled trials. Cowen (1998) suggests that
due to the high risk of side-effects, drugs such as clomipramine or
venlafaxine (with potent serotonin as well as noradrenaline reuptake
inhibition in one medication), may be as effective as TCAs and SSRIs
combined. There may be a role for low dose trazodone to augment SSRIs
but this may just help the sleep disturbance and further studies are
necessary.
A meta-analysis of tri-iodothyronine augmentation of TCA in mixed age
groups showed a response rate of 8% (NNT=13) (Aronson et al., 1996).
There are no studies comparing other classes of antidepressants. It should
be used cautiously if there is co-existing cardiovascular disease. In adults,
L-tryptophan has been shown to enhance the combinations of lithium-MAOI
and lithium-clomipramine (Hale et al., 1987). Again there are no trials in
older patients. With the risk of developing eosinophilic myalgic syndrome
and possible serotonin syndrome with MAOIs and SSRIs, this combination
needs to be used with caution. There is no longer a need to register with
the Optimax (tryptophan) information and clinical support (OPTICS) unit.
Pindolol, a beta blocker with 5-HT1A-receptor antagonist, had been shown
in open studies to augment antidepressants. However, a small double-
blind, placebo-cross over trial showed no difference to placebo (Moreno et
al., 1997). Dexamethasone (Bodani et al., 1999), clonazepam (Morishita
and Aoki, 1999), oestrogen (Stahl, 1998), and methylphenidate (Emptage
et al., 1996) have also all been tried but require further research.
Individual clinicians will invariably have their “preferred” combination of
antidepressants e.g. mirtazapine and clomipramine and mirtazapine plus
an SSRI but the evidence base for these is very poor. In addition, these
combinations require increased monitoring and are not without risks.
Electroconvulsive therapy (ECT)
ECT can be used at any stage alongside the pharmacological management
of treatment resistant depression. It should be noted that SSRIs may
increase seizure length in ECT compared with TCA and may also increase
the risk of post-treatment seizures (Curran, 1995). Shapira et al. (1998)
have shown that the rate of response is more rapid when ECT is given
three times a week but memory impairment is more common and
suggested that the optimum schedule for bilateral ECT in older patients is
twice weekly unless clinical indications require a more rapid antidepressant
effect. Unilateral ECT may have an advantage with respect to cognitive
side effects but Krystal et al (1998) suggest that moderately suprathreshold
unilateral ECT may not be as effective as bilateral ECT for older patients.
He found that older patients were more likely to have a rise in seizure
threshold and to be non-responders to unilateral ECT.
Discontinuing treatment
Antidepressants need to be discontinued slowly (weekly decrements) as all
have the potential to cause a withdrawal syndrome (Hoencamp et al.,
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2000). Typical withdrawal symptoms are anxiety, agitation, insomnia,
dizziness, low mood, paraesthesia, nausea and diarrhoea. When changing
from one antidepressant to another, cross tapering is recommended.
Conclusions
Depression is common and if not treated results in high morbidity and
mortality. Depression in older people generally has a good prognosis. It is
therefore important to diagnose the condition and treat systematically.
When an antidepressant is indicated, it should be chosen on an individual
basis and used at a therapeutic dose for an adequate period. The choice of
antidepressant will depend on a number of factors including previous
response to treatment, concurrent physical illness and other medications.
Pharmacological treatment also needs to be combined with psychosocial
interventions. However, further well-planned research is needed into the
pharmacological management of depression, especially treatment-
resistant, in older people.
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